You may also like
PHVT Disruptive Technology Could Revolutionize Heart Failure Treatment
The early clinical promise of percutaneous heart valve technology-a group of minimally invasive devices designed to treat cardiac valve dysfunction without the need for cardiopulmonary bypass-could one day play a prominent role in curbing the costs associated with treating heart failure, which is the current number-one driver of hospitalization among Medicare patients.
Efficacy and Safety of Aprotinin in Paediatric Cardiac Surgery: A Systematic Review and Meta-Analysis
This meta-analysis suggests that aprotinin is effective and well tolerated in paediatric cardiac surgery. Given the large heterogeneity of the results and the risk of selection bias in observational studies, large randomised controlled trials are warranted.
Effect of Older Donor Age on Risk for Mortality After Heart Transplantation
Donor age as a continuous variable, however, was determined to be a notable predictor of survival and use of the donor age cut-point of 40 years (categorical variable) allowed risk stratification with similar accuracy. The use of a donor age cut-point of 40 years may be a useful clinical criterion for graft-related risk assessment.
